INmune Bio terminates $75M ATM sales agreement with RBC and BTIG effective Dec 19, 2025

Inmune Bio, Inc.

Company notified RBC and BTIG of termination on Dec 5 and Dec 9, 2025; effective Dec 19.
No termination penalties or expenses incurred.
Prior to termination, co. raised ~$10.5M net proceeds through sale of 1,353,469 shares.
Original agreement allowed up to $75M in at-the-market offerings since Aug 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Inmune Bio, Inc. terminated Amended and Restated At-The-Market Sales Agreement with RBC Capital Markets, LLC and BTIG, LLC (effective 2025-12-19).

Action: termination
Agreement: atm program
Counterparty: RBC Capital Markets, LLC and BTIG, LLC
Effective: 2025-12-19

Exact text from the filing

On December 5, 2025 and December 9, 2025, pursuant to and in accordance with Section 12(b) of the Sales Agreement, the Company notified RBC and BTIG, respectively, that the Company is terminating the Sales Agreement, effective December 19, 2025.

View on SEC.gov

Browse all material agreements →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-120067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.